Evolve Biologics
David Holliday has over 30 years of experience in the pharmaceutical industry. David served as the Chief Commercial Officer at Evolve Biologics from April 2017 to the present. Prior to that, they held the same position at Octapharma USA, Inc. from January 2012 to April 2017. At Octapharma, they were responsible for the commercial development of various biologic franchises. Before that, they held Vice President roles at Baxter Healthcare from 2003 to 2011, overseeing global marketing operations and the hemophilia business unit. David also served as a Business Unit Director at Novartis Pharmaceuticals from 1996 to 2003 and at Ciba Pharmaceuticals from 1986 to 1996. Overall, David Holliday has a strong background in commercial strategy and marketing within the pharmaceutical industry.
David Holliday attended Kingston University from 1991 to 1992, where they pursued a degree in Management Studies and earned a DMS. Prior to that, from 1983 to 1984, they studied at Leeds Beckett University, specializing in Banking/Finance and obtaining a BTech National degree.
This person is not in any offices
Evolve Biologics
Evolve Biologics Inc. offers the development and commercialization of plasma-derived therapeutics, using its proprietary PlasmaCap EBA purification technology to more efficiently and effectively meet growing global patient demand for these life-saving products. The Company is currently in the process of commercializing an exciting and innovativeportfolio of product candidates, including IVIG (intravenous immunoglobulin) and Albumin (human serum albumin), both of which are in advanced stages of regulatory approval in the US (FDA) and Canada (Health Canada).